Bio-Techne Corp (NASDAQ:TECH) Director Karen A. Holbrook sold 1,059 shares of Bio-Techne Corp stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $121.73, for a total transaction of $128,912.07. Following the transaction, the director now directly owns 914 shares in the company, valued at $111,261.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Bio-Techne Corp (NASDAQ:TECH) traded down 0.59% during midday trading on Friday, hitting $119.91. 149,056 shares of the company’s stock were exchanged. Bio-Techne Corp has a one year low of $95.68 and a one year high of $124.00. The firm has a market cap of $4.48 billion, a PE ratio of 58.21 and a beta of 0.78. The stock’s 50-day moving average price is $118.21 and its 200 day moving average price is $111.29.

Bio-Techne Corp (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported $1.09 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.10. The business had revenue of $156.60 million for the quarter, compared to analyst estimates of $150.25 million. Bio-Techne Corp had a net margin of 12.93% and a return on equity of 14.18%. The company’s revenue was up 16.2% on a year-over-year basis. During the same period in the prior year, the firm posted $0.92 EPS. Equities research analysts forecast that Bio-Techne Corp will post $3.99 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 18th were issued a dividend of $0.32 per share. The ex-dividend date of this dividend was Wednesday, August 16th. This represents a $1.28 annualized dividend and a dividend yield of 1.07%. Bio-Techne Corp’s payout ratio is currently 65.98%.

COPYRIGHT VIOLATION NOTICE: “Karen A. Holbrook Sells 1,059 Shares of Bio-Techne Corp (TECH) Stock” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/08/karen-a-holbrook-sells-1059-shares-of-bio-techne-corp-tech-stock.html.

TECH has been the topic of a number of analyst reports. BidaskClub downgraded shares of Bio-Techne Corp from a “buy” rating to a “hold” rating in a research note on Tuesday, June 13th. Zacks Investment Research raised shares of Bio-Techne Corp from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a research note on Thursday, July 6th. Wells Fargo & Company initiated coverage on shares of Bio-Techne Corp in a research note on Thursday, July 13th. They set a “market perform” rating on the stock. Finally, Deutsche Bank AG lifted their target price on shares of Bio-Techne Corp from $130.00 to $132.00 and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Bio-Techne Corp has an average rating of “Buy” and an average price target of $127.50.

Several hedge funds have recently made changes to their positions in TECH. Glen Harbor Capital Management LLC lifted its holdings in shares of Bio-Techne Corp by 10.0% during the 1st quarter. Glen Harbor Capital Management LLC now owns 1,848 shares of the biotechnology company’s stock worth $188,000 after acquiring an additional 168 shares during the period. Russell Investments Group Ltd. lifted its holdings in shares of Bio-Techne Corp by 11.5% during the 1st quarter. Russell Investments Group Ltd. now owns 127,512 shares of the biotechnology company’s stock worth $12,962,000 after acquiring an additional 13,117 shares during the period. Oregon Public Employees Retirement Fund lifted its holdings in shares of Bio-Techne Corp by 1.6% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 13,101 shares of the biotechnology company’s stock worth $1,332,000 after acquiring an additional 200 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Bio-Techne Corp by 17.7% during the 1st quarter. Wells Fargo & Company MN now owns 46,182 shares of the biotechnology company’s stock worth $4,695,000 after acquiring an additional 6,955 shares during the period. Finally, Great West Life Assurance Co. Can lifted its holdings in shares of Bio-Techne Corp by 3.8% during the 1st quarter. Great West Life Assurance Co. Can now owns 22,118 shares of the biotechnology company’s stock worth $2,247,000 after acquiring an additional 811 shares during the period. Institutional investors and hedge funds own 98.77% of the company’s stock.

Bio-Techne Corp Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Insider Buying and Selling by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Receive News & Stock Ratings for Bio-Techne Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne Corp and related stocks with our FREE daily email newsletter.